Molecular determinants of response to PD-L1 blockade across tumor types
PD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response to atezolizumab and reveal pathway heterogeneity an...
Main Authors: | Romain Banchereau, Ning Leng, Oliver Zill, Ethan Sokol, Gengbo Liu, Dean Pavlick, Sophia Maund, Li-Fen Liu, Edward Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe June Assaf, Daniel Bower, Namrata Patil, Mark McCleland, David Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti Hegde, Thomas Powles |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-24112-w |
Similar Items
-
New populations and a conservation assessment of <i>Ecbolium hastatum</i> Vollesen
by: Warren McCleland, et al.
Published: (2018-05-01) -
2-(4-Iodophenoxy)acetamide
by: Richard Betz, et al.
Published: (2011-08-01) -
The monoclinic polymorph of dimethylarsinic acid
by: Richard Betz, et al.
Published: (2011-08-01) -
2H-Chromen-4(3H)-one
by: Richard Betz, et al.
Published: (2011-05-01) -
2-Bromo-1-phenylethanone
by: Richard Betz, et al.
Published: (2011-05-01)